U.S. Tech Hardware Stock News

In recent months, Ondas Holdings has announced roughly US$6,000,000 in new counter-drone orders, a US$20,000,000 autonomous border security purchase order, and a US$10,000,000 investment in World View Enterprises to co-develop stratospheric intelligence and surveillance solutions for government and critical infrastructure customers. Together with a planned merger with Mistral Inc. to gain U.S. prime contractor access, these moves deepen Ondas’ role in autonomous defense, border protection,...

Beam Therapeutics recently reported a swing to fourth-quarter 2025 net income of US$244.3 million and entered a long-term, up-to-US$500 million credit facility with Sixth Street to support its sickle cell gene-editing candidate, while also filing a US$144.13 million shelf registration tied to an employee stock plan. At the same time, Beam preserved exclusive access to core base-editing intellectual property through a direct Kobe University license after ending its cross-license with Bio...

Why Enovis stock is back in focus after its latest results Enovis (ENOV) has come back onto investors’ radar after reporting fourth quarter and full year 2025 results that combined continued net losses, sizeable goodwill impairment charges, and fresh 2026 revenue guidance. See our latest analysis for Enovis. Following the earnings release and goodwill impairment news on 26 February, Enovis’ share price has seen a 1 day share price return of 0.78% and a 1 month share price return of 8.5%...

In late February and early March 2026, T-Mobile and UScellular announced they would offer Apple’s new iPhone 17e and iPad Air, alongside Samsung’s Galaxy S26 series, all promoted with rich service bundles and perks that encourage heavier data usage and broader device adoption. For Array Digital Infrastructure, these client device launches point to potentially higher network traffic and capacity requirements, which could increase demand for its infrastructure and services over time. Next,...

Why Progyny stock is back on investors’ radar Progyny (PGNY) is drawing fresh attention after reporting fourth quarter and full year 2025 earnings, pairing that update with a completed share buyback, cautious 2026 revenue guidance, and a new ESOP related shelf registration. See our latest analysis for Progyny. Progyny’s recent earnings update, buyback completion, and ESOP related shelf registration have arrived against a weak share price backdrop, with a 30 day share price return of 16.58%...

Apple (AAPL) continues to draw attention as investors weigh its recent share performance against the company’s scale, with annual revenue of about US$435.6b and net income near US$117.8b. See our latest analysis for Apple. At a latest share price of US$257.46, Apple’s recent 1 month share price return of 7.43% and year to date share price return of 5.00% contrast with a 1 year total shareholder return of 13.67%. This sits alongside very strong 3 year and 5 year total shareholder returns of...

Recent performance context for Apellis Pharmaceuticals (APLS) With no single headline event driving recent trading, investors looking at Apellis Pharmaceuticals (APLS) today are weighing a commercial stage biotech that reports revenue of US$1,003.8m and net income of US$22.4m. See our latest analysis for Apellis Pharmaceuticals. At a share price of US$20.07, Apellis Pharmaceuticals has a 1 month share price return of 14.6% and a year to date share price decline of 22.4%. The 1 year total...

Hancock Whitney (HWC) has drawn investor attention following recent share price weakness, with the stock declining 3.2% over the past day and 15.5% over the past month. See our latest analysis for Hancock Whitney. Despite the recent setback, the latest 30 day share price return of a 15.5% decline and a softer year to date share price return sit alongside a 1 year total shareholder return of 28.3%. This suggests earlier momentum has cooled, even though longer term holders remain ahead. If the...

Crescent Energy recently completed a US$600 million Rule 144A offering of 2.75% senior unsecured convertible notes due March 15, 2031, alongside filing a US$12.12 million shelf registration for 1,035,228 Class A shares tied to its ESOP. These capital moves follow a shift from a full-year net loss to US$132.91 million in net income in 2025, highlighting greater financial flexibility and evolving employee ownership. We’ll now examine how the new US$600 million convertible notes may influence...

In late February and early March 2026, The Goldman Sachs Group, Inc. issued a wide range of new bonds and notes, from short-dated floating-rate instruments to long-dated callable senior unsecured debt, as part of its ongoing use of shelf registrations to access funding and refine its capital structure. At the same time, rising geopolitical tensions, higher oil prices and concerns over inflation and private credit risks have amplified risk perceptions around large investment banks like...

Why AdaptHealth’s latest results matter for investors AdaptHealth (AHCO) recently reported full year 2025 results that shifted from profit to a net loss, alongside a sizeable goodwill impairment and fresh 2026 revenue guidance. This gives investors several moving pieces to assess. For 2025, AdaptHealth reported sales of US$3.24b compared with US$3.26b a year earlier, while net income swung to a loss of US$70.79m from net income of US$90.42m in the prior year. The company also recorded an...

In late February 2026, Charter Communications appointed veteran telecom executive Nick Jeffery as Chief Operating Officer, tasking him with leading Marketing and Sales, Field Operations and Customer Operations across Spectrum’s residential and business services from September 1, 2026. Jeffery’s track record of operational overhauls and customer satisfaction gains at Frontier Communications and Vodafone UK signals a meaningful shift in how Charter may approach service quality and execution...

In early March 2026, Helmerich & Payne reported a first-quarter fiscal 2026 adjusted net loss that missed analyst expectations, driven by weakness in its North America Solutions segment and a sizeable non-cash impairment charge, even as international operations supported revenue. At the same time, the company continued returning cash to investors through a US$0.25 per-share quarterly dividend and advanced debt reduction plans, highlighting a focus on capital discipline despite operating...

Recent performance snapshot With no single news headline driving attention today, Tradeweb Markets (TW) is drawing interest after a recent share price of $124.59 and a mixed return picture, including a 17.3% gain year to date alongside a 6% decline over the past year. See our latest analysis for Tradeweb Markets. Recent trading has been positive, with a 30 day share price return of 11.11% and a year to date share price return of 17.32%, set against a 1 year total shareholder return decline of...

In late February 2026, Chord Energy reported Q4 2025 revenue of US$1,169.44 million and net income of US$84.42 million, alongside updated production guidance, a US$1.30 per-share base dividend declaration, and a completed US$47.83 million buyback tranche. An interesting angle is that management highlighted materially lower finding and development costs and projected US$700 million in 2026 free cash flow, after having returned US$6.70 billions to shareholders since 2021. We’ll now examine how...

Why Indivior Pharmaceuticals Stock Is Back on Investors’ Radar Indivior Pharmaceuticals (INDV) recently reported higher earnings for 2025, reaffirmed its 2026 revenue guidance of US$1,125 million to US$1,195 million, and announced a new US$400 million share repurchase plan. See our latest analysis for Indivior Pharmaceuticals. Despite the strong earnings update and US$400 million buyback news, the share price has had a 30 day share price return of a 6.08% decline and a 90 day share price...

JFrog (FROG) has been back in focus after a sharp swing, driven first by executive stock sales and then by a rebound tied to stronger sector sentiment following Broadcom’s upbeat AI related revenue outlook. See our latest analysis for JFrog. Those swings sit against a weaker recent trend, with a 30 day share price return of 15.42% and a 90 day share price return of 41.03%. This is the case even though the 1 year total shareholder return is 20.91% and the 3 year total shareholder return is...

In early March 2026, Southern Copper faced renewed pressure as analyst downgrades, softer copper prices tied to China’s lower growth target, a stronger US dollar, and geopolitical tensions all weighed on sentiment despite previously strong quarterly earnings. Adding to the uncertainty, insider share sales and unusually active, mixed options positioning by large investors highlighted growing debate over the company’s near-term outlook. Next, we’ll explore how this wave of downgrades and...

In early March 2026, Northern Trust announced it had been appointed to provide fund administration, global custody, financial reporting and transfer agency services to Netherlands-based CK Capital Partners’ CK Capital Value Fund Cooperatief U.A., alongside expanding its CLO middle-office capabilities and adding Berenberg’s AI-driven models to its dynamic currency hedging framework. These developments highlight Northern Trust’s push to deepen its role in complex asset servicing and risk...

Recent performance snapshot for Lindblad Expeditions Holdings (LIND) Lindblad Expeditions Holdings (LIND) has drawn attention after recent share price swings, with a 2% decline over the past day and an 8% move lower over the past week catching investor eyes. Over the past month the stock shows an 11% decline, while the past 3 months reflect a 42.6% total return. This sets up a contrasting short term and medium term performance picture that investors may want to unpack. See our latest analysis...

In late February 2026, Soleno Therapeutics reported that it moved from a US$55.98 million quarterly loss to a US$43.36 million quarterly profit and filed an approximately US$81.90 million shelf registration for over 2.09 million common shares tied to an employee stock ownership plan. The company also announced a CFO transition, bringing in experienced pharma and capital markets executive Jennifer Fulk just as Soleno’s earnings profile and capital structure are evolving. We’ll now examine how...

Why Broadcom’s latest earnings have refocused attention on its AI story Broadcom (AVGO) just delivered an earnings beat built on record AI semiconductor revenue, a projection of more than US$100b in AI chip sales in 2027, and a fresh US$10b share repurchase plan. See our latest analysis for Broadcom. Despite a modest 3.7% 7 day share price return and a 4.9% year to date decline, Broadcom’s very large 5 year total shareholder return of around 7x shows long term holders have still been well...

What Chime Financial’s recent performance means for investors Chime Financial (CHYM) has drawn investor attention after a recent pullback, with the stock down 3.8% over the past day and 1.7% over the past week, while posting a modest gain over the past month. Against that mixed share performance, the company reports US$2,186.77m in revenue and a net loss of US$1,009.94m. This provides a snapshot of a fintech platform that is generating significant revenue yet is still operating at a loss. See...

Sunstone Hotel Investors recently reported past fourth-quarter and full-year 2025 results, showing higher quarterly sales and a return to profitability alongside lower full-year net income, and issued 2026 net income guidance of US$21 million to US$46 million. The company also maintained its quarterly dividend and filed an omnibus shelf registration for common and preferred stock and depositary shares, signaling both ongoing capital returns and potential future fundraising flexibility. We’ll...